Company: NDRA
Filing Date: 2025-10-17
Form Type: PRE 14A
Source: 0001654954-25-011931
Chunk: 57

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-17
Form: PRE 14A
Chunk 57
---
6 Plan and to any outstanding awards, and in the option price, SAR exercise price or purchase price per share of any outstanding awards in order to prevent dilution or enlargement of grantees’ rights under the 2016 Plan. If a majority of the shares which are of the same class as the shares that are subject to outstanding awards are exchanged for, converted into, or otherwise become shares of another corporation, the Board may unilaterally amend the outstanding awards to provide that such awards are for such new shares. In the event of any such amendment, the number of shares subject to, and the option price, SAR exercise price or purchase price per share of, the outstanding awards will be adjusted in a fair and equitable manner. The Board may also make such adjustments in the terms of any award to reflect, or related to, such changes in the capital structure of the Company or distributions as it deems appropriate.

Change in Control

Subject to applicable law, the Board may provide for any one or more of the following in connection with a “change in control” (as defined in the 2016 Plan and summarized below), which such actions need not be the same for all grantees.

The Board may provide in any award agreement, or in the event of a change in control may take such actions as it deems appropriate to provide, for the acceleration of the exercisability, vesting and/or settlement in connection with such change in control of each or any outstanding award or portion thereof and shares acquired pursuant thereto upon such terms and conditions, including a grantee’s separation from service prior to, upon, or following such change in control, to such extent as determined by the Board.

In the event of a change in control, the surviving, continuing, successor or purchasing corporation or other business entity or parent thereof, as the case may be, may, without the consent of any grantee, either assume or continue the Company’s rights and obligations under each or any award or portion thereof outstanding immediately prior to the change in control or substitute for each or any such outstanding award or portion thereof a substantially equivalent award with respect to the acquiror’s stock, as applicable. Any award or portion thereof which is neither assumed or continued by the acquiror in connection with the change in control nor exercised or settled as of the time of consummation of the change in control will terminate and cease to be outstanding effective as of the time of consummation of the change in control.

The Board may, without the consent of any grantee